JAGSNPHARM233.84

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,566 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)247.69302.46331.70331.70
Receivable Days (DSO)19.1517.9021.8521.85
Payable Days (DPO)125.45193.69262.34270.15
Cash Conversion Cycle (days)141.39126.6791.2183.40
Working Capital Turnover1.161.992.502.56
Asset Turnover0.960.970.910.91
Cash Conversion (CFO/Net Income)1.571.001.091.09
CFO/EBITDA1.521.080.810.81
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.